Sagimet Biosciences (SGMT)
Develops selective FASN inhibitors for metabolic, dermatology, and oncology indications.
$11.15
Pre-market+0.15 (+1.36%)
At close$11.00(+4.76%)
Something off on this page? Send us feedback.
Breakdown13F · 13D/G · Form 4
| Institutions93 holders · as of Mar 31, 2026 | 42.97% | 26.71M shares | |
| Insiders5 holders · as of Aug 17, 2026 | 1.99% | 1.24M shares | |
| Otherremainder | 55.04% | 34.22M shares |
62.16M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Two share counts disagree (62.16M in the company's Sep 3, 2026 report, 32.58M elsewhere); stakes use the report.
This company has 2 share classes; every stake here is a share of the whole company.
Institutions13F, as of Mar 31, 2026
93 holders · 13.35M shares · 18 new positions · 51 increased · 17 reduced · 17 closed
| Holder | Shares | % of company | Chg q/q | Filed |
|---|---|---|---|---|
| Vanguard Capital Management LLC | 1.10M | 1.77% | +1.10Mnew | May 15, 2026 |
| Woodline Partners LP | 1.00M | 1.61% | 0 | May 15, 2026 |
| Marshall Wace, LLP | 966.3K | 1.55% | +185.8K | May 15, 2026 |
| Baker Bros. Advisors LP | 953.0K | 1.53% | 0 | May 15, 2026 |
| Affinity Asset Advisors, LLC | 868.0K | 1.40% | −280.2K | May 14, 2026 |
| Millennium Management LLC | 862.3K | 1.39% | +275.4K | May 15, 2026 |
| BlackRock, Inc. | 799.9K | 1.29% | −14.0K | May 13, 2026 |
| HHLR Advisors, Ltd. | 724.8K | 1.17% | 0 | May 15, 2026 |
Ownership statements13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 7.80% | 4.75M | 13G | Jul 30, 2026 ↗ |
| Balyasny Asset Management L.P. | 5.93% | 3.63M | 13G | Aug 14, 2026 ↗ |
Insider tradesForm 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Aug 14, 2026 | George Kembledirector | Sale | 350,987 | $10.23 | 62,161 |
| Aug 11, 2026 | George Kembledirector | Sale | 20,206 | $9.95 | 62,161 |
| Jul 20, 2026 | George Kembledirector | Sale | 18,844 | $7.46 | 62,161 |
| Jul 20, 2026 | Elizabeth Rozekofficer: Chief Legal & Admin. Officer | Sale | 10,545 | $7.76 | 224,414 |
| Jul 20, 2026 | David Happeldirector, officer: President & CEO | Sale | 64,051 | $7.76 | 741,570 |
| Feb 10, 2026 | Elizabeth Rozekofficer: Chief Legal & Admin. Officer | Sale | 2,622 | $5.36 | 190,959 |
| Feb 10, 2026 | Eduardo Bruno Martinsofficer: Chief Medical Officer | Sale | 3,640 | $5.36 | 103,296 |
| Feb 10, 2026 | Thierry Chaucheofficer: Chief Financial Officer | Sale | 1,312 | $5.36 | 15,688 |
| Feb 10, 2026 | David Happeldirector, officer: President & CEO | Sale | 12,101 | $5.36 | 677,621 |
| Nov 20, 2025 | George Kembledirector, officer: Executive Chairman | Sale | 37,688 | $7.69 | 81,005 |
CongressHouse and Senate disclosures
Not reported.